Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.56 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100780 | 0.88 | CYP4F2 (0.62) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL22190459 | 0.85 | CYP4F2 (0.69) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL2021436 | 0.84 | CYP4F2 (0.67) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL4577570 | 0.83 | CYP4F2 (0.56) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL19875578 | 0.83 | MMP8 (0.49) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL10816623 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL3283635 | 0.81 | CYP4F2 (0.50) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL6762091 | 0.81 | MEN1 (0.55) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL10815184 | 0.81 | CYP4F2 (0.39) | CYP4F2CYP4A11TSHRMEN1KMT2A | |
| SCHEMBL5306680 | 0.80 | CYP4F2 (0.62) | CYP4F2CYP4A11TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034517-B1 | Capacitors having conditioned carbon for electrodes | Retriev Technologies Incorporated (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2015069854-A1 | ELECTROLYTE SOLUTION FOR CAPACITORS AND BATTERIES | Retriev Technologies Incorporated (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150125760-A1 | CAPACITORS HAVING CONDITIONED CARBON FOR ELECTRODES | SOLSTICE ADVANCED MATERIALS US, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8785057-B1 | Electrolyte solution for capacitors and batteries | Retriev Technologies Incorporated (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8420641-B2 | Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120264773-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| US-20120208816-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2463282-A1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20070002522-A1 | Electric double layer capacitor and electrolytic solution therefor | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-01-04 | — | — | US | disclosed |
| US-5075488-A | Fungicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0128006-B1 | A SOIL-DISEASE-CONTROLLING AGENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-4709052-A | FUNGICIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-11-24 | — | — | US | disclosed |
| EP-0128006-A2 | A soil-disease-controlling agent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
| US-4479963-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0105919-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES. | CIBA GEIGY AG (CH) | 1984-04-25 | — | — | EP | disclosed |
| WO-1983003828-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1983-11-10 | — | — | WO | disclosed |
| US-4401818-A | HYPOTENSIVE AGENTS, CARDIOACTIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-08-30 | — | — | US | disclosed |
| US-4374847-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264773-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CYP4F2 492/4885CYP4A11 105/4885TSHR 1637/4885 |
| US-20120208816-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CYP4F2 492/4885CYP4A11 105/4885TSHR 1637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.